COVID-19 vaccine, protein subunit, Sepivac SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1
COVID-19 vaccine, protein subunit, SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1
SARS-CoV-2, subunit vaccine, broad protection, vaccine platform, emerging coronaviruses, Syrian hamsters
SARS-CoV-2, neutralization, variants of concern, omicron, vaccine, neutralizing antibodies